stoxline Quote Chart Rank Option Currency Glossary
  
uniQure N.V. (QURE)
6.8  0.07 (1.04%)    11-13 16:00
Open: 6.73
High: 7.15
Volume: 635,265
  
Pre. Close: 6.73
Low: 6.7
Market Cap: 331(M)
Technical analysis
2024-11-13 4:47:06 PM
Short term     
Mid term     
Targets 6-month :  9.29 1-year :  10.85
Resists First :  7.96 Second :  9.29
Pivot price 6.61
Supports First :  6.27 Second :  5.23
MAs MA(5) :  7.28 MA(20) :  6.57
MA(100) :  6.31 MA(250) :  5.92
MACD MACD :  0.3 Signal :  0.2
%K %D K(14,3) :  65.6 D(3) :  78.9
RSI RSI(14): 54.4
52-week High :  11.35 Low :  3.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ QURE ] has closed below upper band by 42.9%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.15 - 7.19 7.19 - 7.22
Low: 6.62 - 6.66 6.66 - 6.69
Close: 6.74 - 6.8 6.8 - 6.86
Company Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Headline News

Fri, 08 Nov 2024
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade - Yahoo Finance

Thu, 07 Nov 2024
What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates - Yahoo Finance

Wed, 06 Nov 2024
QURE - uniQure N.V. Latest Stock News & Market Updates - StockTitan

Tue, 05 Nov 2024
uniQure N.V. Reports Q3 2024 Progress and Financials - TipRanks

Tue, 05 Nov 2024
UniQure: Q3 Earnings Snapshot - San Antonio Express-News

Tue, 05 Nov 2024
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 49 (M)
Shares Float 40 (M)
Held by Insiders 4.3 (%)
Held by Institutions 75 (%)
Shares Short 5,730 (K)
Shares Short P.Month 4,270 (K)
Stock Financials
EPS -4.95
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.34
Profit Margin 0 %
Operating Margin -426 %
Return on Assets (ttm) -17.2 %
Return on Equity (ttm) -126.5 %
Qtrly Rev. Growth 359.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.56
EBITDA (p.s.) -4.46
Qtrly Earnings Growth 0 %
Operating Cash Flow -104 (M)
Levered Free Cash Flow -68 (M)
Stock Valuations
PE Ratio -1.38
PEG Ratio 0
Price to Book value 1.56
Price to Sales 11.96
Price to Cash Flow -3.19
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android